Chemoprevention of metachronous adenomatous colorectal polyps

• US 5,945,411 A
• Filed: 09/23/1998
• Issued: 08/31/1999
• Est. Priority Date: 03/22/1996
• Status: Expired due to Fees

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Pearson, Randall K., Larson, Mark V., Ahlquist, David A.
• Primary Examiner(s): Goldberg, Jerome D.
• Application Number:
  US09/158,871
• Time in Patent Office: 342 Days
• Field of Search: 514/171
• US Class Current: 514/171
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/575 substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

A method for protecting a colorectum against a recurrence of adenomas is provided, wherein ursodeoxycholic acid or an amide-conjugate thereof, or ursodeoxycholic acid or an amide-conjugate thereof in combination with sulindac or a phenolic NSAID is administered to a patient afflicted with colorectal adenomas in an amount effective to prevent the recurrence of colorectal adenomas following the removal thereof.

Claims

1. A method for protecting a colorectum against a recurrence of colorectal adenomas comprising administering to a human afflicted with colorectal adenomas, an amount of ursodeoxycholic acid or a pharmaceutically-acceptable salt thereof, effective to prevent the recurrence of colorectal adenomas following the removal thereof and administering an effective amount of a nonsteroidal anti-inflammatory agent, wherein the nonsteroidal anti-inflammatory agent is a phenolic NSAID.

2. The method of claim 1 wherein the phenolic NSAID is mesalamine.

3. The method of claim 2 wherein the effective amount of a mesalamine is administered orally.